Press Releases
-
Nov 2, 2020
If approved, 1st Therapy in U.S. for the Treatment of AchondroplasiaBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for vosoritide, an investigational, once...
-
Oct 22, 2020
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday,...
Oct 7, 2020New Safety and Efficacy Data Out to 3 Years for First and Only Enzyme Therapy to Treat PKU Demonstrate Phe Lowering and Support Well-Characterized Safety ProfileBioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) to increase the...
Oct 5, 2020From Dish to Bedside: Tenured Harvard Professor, Started Multiple Biotechs, to Grow Early Stage PipelineBioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the Company hired scientific luminary and MacArthur Fellowship winner, Kevin Eggan, Ph.D., as Group Vice President, Head of Research and...
-
Oct 2, 20202nd Investigational Gene Therapy in Clinic, Potential 3rd Therapy in PKU Franchise, 15+ Year Commitment to PKU Community
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a pioneer in developing treatments for phenylketonuria (PKU) and gene therapies, announced today that the U.S. Food and Drug Administration (FDA) has...